Clinical trials · New York
Advanced Lung Cancer clinical trials in New York
We’re tracking 212 recruiting advanced lung cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
New York, New YorkAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
New York, New YorkAges 18 years+ - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
New York, New YorkAges 18 years+ - NCT07391956Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether special supportive care (called tiered palliative care) can help people with advanced heart failure or certain advanced cancers feel better and have fewer hospital visits. If you live in Manhattan or Queens, speak English or Spanish, and meet the other requirements, you may be able to join.
Astoria, New YorkAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New York, New YorkAges 18 years+ - NCT07227480Recruiting
Lung cancer screening help via text message
This study uses text messages to help people get their yearly lung cancer screening. If you're between 50–80, have a significant smoking history, and haven't completed your annual screening yet, you may be able to join from home.
Rochester, New YorkAges 50–80 - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Albany, New YorkAges 18 years+ - NCT07227298RecruitingPhase 1/Phase 2
Study of PF-08634404 with other cancer drugs for advanced lung cancer
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
The Bronx, New YorkAges 18 years+ - NCT07185997RecruitingPhase 3
Study of Firmonertinib for first-line treatment of advanced lung cancer with uncommon EGFR mutations
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
Lake Success, New YorkAges 18 years+ - NCT07080242RecruitingPhase 1
Study of BL-M14D1 for small cell lung cancer and neuroendocrine tumors
This trial tests an investigational drug, BL-M14D1, for people with certain types of neuroendocrine tumors or small cell lung cancer that have progressed after standard treatment. The drug targets a protein called DLL3 found on these cancer cells, which may help shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
New York, New YorkAges 18–75 - NCT07027514RecruitingPhase 1
Combination treatment for advanced lung cancer
This study tests a new drug called tolododekin alfa combined with an approved immunotherapy drug for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective.
New York, New YorkAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06963723Recruiting
Screening for financial hardship in advanced cancer
This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.
New York, New YorkAges 21 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
New York, New YorkAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
New York, New YorkAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
New York, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Syracuse, New YorkAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
New York, New YorkAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
New York, New YorkAges 18–100 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
New York, New YorkAges 18 years+
Advanced Lung Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- NYU Langone Health · 4 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Montefiore Medical Center · 2 studies
- Avenzo Therapeutics Recruiting Site
- Clinical Research Alliance
What taking part in a advanced lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Lung Cancer trials in other states
Common questions
- Are there advanced lung cancer clinical trials in New York?
- Yes. We're currently tracking 212 recruiting advanced lung cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced lung cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced lung cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.